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ABSTRACT
Background. Colon cancer in older patients represents a major
public health issue. As older patients are hardly included in
clinical trials, the optimal treatment of these patients remains
unclear. The present international EURECCA comparison explores
possible associations between treatment and survival outcomes
in elderly colon cancer patients.
Subjects, Materials, and Methods. National data from Belgium,
Denmark, The Netherlands, Norway, and Sweden were obtained,
as well as a multicenter surgery cohort from Germany. Patients
aged 80 years and older, diagnosed with colon cancer between
2001 and 2010, were included. The study interval was divided
into two periods: 2001–2006 and 2007–2010. The proportion of
surgical treatment and chemotherapy within a country and its
relation to relative survival were calculated for each time frame.
Results. Overall, 50,761 patients were included. At least 94%
of patients with stage II and III colon cancer underwent
surgical removal of the tumor. For stage II–IV, the proportion
of chemotherapy after surgery was highest in Belgium and
lowest in The Netherlands and Norway. For stage III, it varied
from 24.8% in Belgium and 3.9% in Norway. For stage III,
a better adjusted relative survival between 2007 and 2010
was observed in Sweden (adjusted relative excess risk [RER]
0.64, 95% conﬁdence interval [CI]: 0.54–0.76) and Norway
(adjusted RER 0.81, 95% CI: 0.69–0.96) compared with
Belgium.
Conclusion. There is substantial variation in the rate of treat-
ment and survival between countries for patients with colon
cancer aged 80 years or older. Despite higher prescription
of adjuvant chemotherapy, poorer survival outcomes were
observed in Belgium. No clear linear pattern between the pro-
portion of chemotherapy and better adjusted relative survival
was observed.The Oncologist 2018;23:1–9
Implications for Practice: With the increasing growth of the older population, clinicians will be treating an increasing number of
older patients diagnosed with colon cancer. No clear linear pattern between adjuvant chemotherapy and better adjusted relative
survival was observed. Future studies should also include data on surgical quality.
INTRODUCTION
Worldwide, one third of all new colon cancer patients are aged
75 years or older [1]. With increasing life expectancy, the num-
ber of older colon cancer patients is increasing markedly [2],
while evidence from randomized controlled trials for treatment
of these patients remains scarce. Older patients may have
more comorbidities and frailty that can inﬂuence their surgical
eligibility [3]. For patients with stage III colon cancer, adjuvant
chemotherapy is recommended [4–6] in order to reduce
recurrence rate and improve cancer-speciﬁc survival [7–9].
For stage II patients, however, the use of adjuvant therapy is
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still controversial. Especially in the elderly, the beneﬁt of
adjuvant chemotherapy is debatable. Currently, chemother-
apy with ﬂuoropyrimidines (5-ﬂuorouracil [5-FU] or capecita-
bine) is recommended in older (>70 years) colon cancer
patients [4].
The aim of this international comparison is to compare
treatment strategies and relative survival (RS) between coun-
tries for older patients with colon cancer, using data from
population-based cancer registries across Europe.
SUBJECTS, MATERIALS, AND METHODS
Study Design
Patients aged 80 years or older diagnosed with colon cancer
between 2001 and 2010 were included. Data were collected
from six European countries: ﬁve national cancer registries and
one multicenter cohort from Germany. Three national datasets
were obtained from national cancer registries: the Belgian
Cancer Registry (BE; 2004–2010), The Netherlands Cancer
Registry (NL; 2001–2010), and the Norwegian Cancer Registry
(NO; 2001–2010), supplemented with data from the Norwegian
Colorectal Cancer Registry (2007–2010) [10]. Denmark (DK)
and Sweden (SE) provided data from national clinical quality
databases: the Danish Colorectal Cancer Group database
(2001–2010) and the Swedish Colorectal Cancer Registry
(2007–2010). National datasets (BE, DK, NL, NO, and SE) were
included and merged. The cohort ended in June 2014. Data
from Germany were not from a national dataset and included
only patients who had undergone surgery, and follow-up data
(2001–2004, 2008–2010) were not fully available. Data from
Germany were therefore not included in the main analyses but
are shown in supplemental online Table 1. Because 5-year sur-
vival for colon cancer has improved over time [11, 12], two
time periods according to the different periods for including
patients were analyzed: 2001–2006 and 2007–2010. Further-
more, the RS over time, according to country, stage, and period,
is shown in supplemental online Table 2.
Quality of the data in terms of completeness (>95% of can-
cer patients in the population are registered) and accuracy
(data on individual cancer patients must be correct) was guar-
anteed by the cancer registries. Only primary colonic cancers
were included. Of patients with metachronous colon cancer,
only data of the tumor with highest stage were included for
analyses. The pathological tumor stage was provided by the
cancer registries, deﬁned using the TNM Classiﬁcation of Malig-
nant Tumors for colon cancer, 5th, 6th, or 7th edition [13, 14].
In case pathological stage was missing, clinical tumor stage was
used. Vital status and date of last follow-up were established
either directly from the patient’s medical records or through
linkage of cancer registry data with municipal population regis-
tries for all countries. Death Certiﬁcate Only patients were
excluded from the analyses. Follow-up time for vital status was
calculated from date of diagnosis until death, from merge with
Municipal Records Database or until end of follow-up (cen-
sored). Patients were excluded from survival analyses if follow-
up data were unavailable or vital status was missing.
Treatment and Outcome
The main outcome was RS expressed as relative excess risk
(RER) for each country, compared with a reference category.
The secondary outcome was the proportion of given chemo-
therapy after surgery. The deﬁnition of surgery was not
uniformly deﬁned among participating countries. In this inter-
national comparison, surgical treatment was deﬁned as surgical
removal of the tumor, irrespective of curative or palliative
intent. Colon resections as well as local removal of the tumor
were included. Laparotomy without resection and defunction-
ing procedures only were not registered as surgical treatment.
The proportion of patients receiving surgical treatment accord-
ing to stage was compared. Adjuvant chemotherapy was
deﬁned as the proportion of patients with stage I–III colon can-
cer who received chemotherapy after surgical treatment. For
patients with stage IV colon cancer, chemotherapy is most likely
given with palliative intent. Stage IV colon cancer encompasses
various clinical conditions and differences in prognosis accord-
ing to the number and location of metastatic organs. To
enhance the uniformity of the data of this group of patients,
we chose to determine the proportion of administered chemo-
therapy in patients who underwent resection of the primary
tumor. Data on surgery were complete for all patients. Data on
chemotherapy were missing for 0.9% and, in contrast to surgi-
cal data, of lower quality for some countries. For example, in
Norway, data are based on clinical notiﬁcations of planned
treatment and not the actual received treatment. The trend of
chemotherapy use in different countries was compared with
the trend in adjusted RS. In the survival analyses, all patients
were included, regardless of treatment modality.
Statistical Analysis
All analyses were stratiﬁed for stage of disease. Logistic regres-
sion was used to compare the proportion of surgery and chem-
otherapy between countries, with adjustment for sex, age, and
incidence year. For each country, 5-year RS was calculated as
the ratio of the survival observed among the patients diag-
nosed with colon cancer and the survival that would have been
expected based on the corresponding general population,
adjusted for age, sex, and year (Ederer II method) [15]. National
life tables of each speciﬁc country were used to estimate
expected survival. To quantify the relative cancer-related excess
mortality between the countries, RER of death was used [16].
RER for countries was estimated using a multivariable general-
ized linear model with a Poisson distribution, based on col-
lapsed relative survival data, using exact survival times, adjusted
for age, sex, and year of diagnosis. The country with the highest
proportion of chemotherapy was used as reference category. A
higher RER indicates a lower RS. A two-sided p value <.05 was
considered as statistically signiﬁcant. All analyses were per-
formed in STATA/SE 12.0 (StataCorp, College Station, TX).
RESULTS
Patients and Tumor Characteristics
In total, 50,761 patients with colon cancer aged 80 years and
older, diagnosed between 2001 and 2010, were included. The
numbers of inhabitants per country are described in Table 1. In
the cancer registries, follow-up for vital status was complete for
99.9%. Median follow-up was 1.6 years (interquartile range
[IQR] 0.3–3.8 years). Median follow-up for patients alive at
the end of follow-up was 3.9 years (IQR 2.5–5.8 years). No dif-
ferences in stage (p5 .39) and grade (p5 .40) were observed
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in patients with known and unknown follow-up status. Median
age was 84 years within every country (range 80–104 years). In
Denmark, a lower proportion of stage I (9.3% in DK vs. 16.2% in
NO) and a higher proportion of stage IV (26.4% in DK vs. 14.2%
in BE) were found (Table 1).
Treatment Comparison
As shown in Table 2, the proportion of patients with stage I
colon cancer receiving surgical treatment differed substantially
between countries. It was lowest in Belgium (2001–2006:
86.4% and 2007–2010: 82.6%) and highest in The Netherlands
(2001–2010: 98.7%). Only a minority of patients were treated
with local excision (0.2%–2.8%). The proportion of patients
with stage II and III colon cancer undergoing surgery exceeded
94% within every country. Between 2007 and 2010, surgical
treatment for stage IV was most pronounced in Belgium
(59.8%) and Sweden (68.1%) compared with that in Denmark
(40.9%). The proportion of elderly patients who received adju-
vant chemotherapy for stage III colon cancer varied between
24.8% (BE) and 3.9% (NO) between 2007 and 2010. For patients
with stage IV colon cancer, chemotherapy administration after
surgical treatment varied between 39.0% (BE) and 10.3% (NO).
Survival
For all countries, decline in RS was most pronounced in the ﬁrst
year (supplemental online Figs. 1, 2). RS increased between
2001–2006 and 2007–2010 for The Netherlands, Denmark, and
Norway, but not for Belgium (between 2004–2006 and 2007–
2010; supplemental online Table 1). As shown in Table 3, for
stage I, a signiﬁcantly higher RER (lower RS) was observed in
Norway compared with Belgium between 2001 and 2006
(adjusted RER 1.89, 95% CI: 1.03–3.44, p 5 .04). For stage II,
between 2001 and 2006, Denmark had higher RER compared
with Belgium (adjusted RER 1.26, 95% CI: 1.01–1.57, p 5 .04).
Between 2007 and 2010, these differences were no longer sig-
niﬁcant for Norway (stage I) and Denmark (stage II). For
patients with stage III disease, a signiﬁcantly better adjusted RS
was observed in Sweden (adjusted RER 0.64, 95% CI: 0.54–
0.76, p< .001) and Norway (adjusted RER 0.81, 95% CI: 0.69–
0.96, p5 .01) compared with Belgium between 2007 and
2010. Denmark, The Netherlands, and Norway showed higher
RER compared with Belgium for stage IV disease between 2007
and 2010.
Survival in Relation to Treatment
Figures 1 and 2 show the proportion of patients receiving
chemotherapy and the adjusted RERs by country. The propor-
tion of administered chemotherapy is determined in patients
who underwent resection of the primary tumor; RS is calcu-
lated for the country. For stage III, between 2001 and 2006,
trends in the proportions of chemotherapy administered in
Belgium, Denmark, and The Netherlands were not reﬂected in
Table 1. Patient and tumor characteristics for patients aged 80 years and older diagnosed with colon cancer (2001–2010),
according to country
Characteristics
Belgium
n5 9,484
n (%)
Denmark
n5 6,182
n (%)
Germany
n5 4,920
n (%)
Sweden
n5 4,393
n (%)
The Netherlands
n5 17,803
n (%)
Norway
n5 7,979
n (%)
Inhabitantsa, in millions 10.5 5.4 82.5 9.0 16.3 4.6
Age, years, median (range) 84 (80–103) 84 (80–104) 84 (80–101) 84 (80–99) 84 (80–104) 84 (80–101)
Gender
Male 4,011 (42.3) 2,518 (40.7) 1,654 (33.6) 1,870 (42.6) 7,259 (40.8) 3,114 (39.0)
Female 5,473 (57.7) 3,664 (59.3) 3,266 (66.4) 2,523 (57.4) 10,544 (59.2) 4,865 (61.0)
Stage
I 1,115 (11.8) 575 (9.3) 691 (14.0) 498 (11.4) 2,406 (13.5) 1,296 (16.2)
II (T3–4N0) 3,198 (33.7) 2,125 (34.4) 1,780 (36.2) 1,499 (34.1) 6,267 (35.2) 2,421 (30.3)
III (any TN1–2) 2,313 (24.4) 1,321 (21.4) 1,398 (28.4) 1,047 (23.8) 3,867 (21.7) 1,743 (21.8)
IV 1,349 (14.2) 1,629 (26.4) 885 (18.0) 739 (16.8) 2,876 (16.2) 1,556 (19.5)
Unknown 1,509 (15.9) 532 (8.6) 166 (3.4) 610 (13.9) 2,387 (13.4) 963 (12.1)
Tumor grade
I 1,407 (14.8) — 227 (4.6) 309 (7.0) 1,101 (6.2) —
II 4,361 (46.0) — 3,172 (64.5) 2,523 (57.4) 9,350 (52.5) —
III 1,541 (16.3) — 1,244 (25.3) 920 (21.0) 3,064 (17.2) —
Unknown 2,175 (22.9) 6,182 (100) 277 (5.6) 641 (14.6) 4,288 (24.1) 7,979 (100)
Incidence year
2001–2002 — 976 (15.8) 1,902 (38.7) — 2,726 (15.3) 1,362 (17.1)
2003–2004 1,202 (12.7)b 1,189 (19.2) 2,080 (42.3) — 3,220 (18.1) 1,488 (18.6)
2005–2006 2,486 (26.2) 1,363 (22.1) — — 3,523 (19.8) 1,633 (20.5)
2007–2008 2,797 (29.5) 1,312 (21.2) 282 (5.7) 2,117 (48.2) 4,043 (22.7) 1,704 (21.4)
2009–2010 2,999 (31.6) 1,342 (21.7) 660 (13.3) 2,276 (51.8) 4,291 (24.1) 1,792 (22.5)
aNumber of inhabitants in 2005.
bBelgium: inclusion from 2004.
Abbreviation: —, no data.
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signiﬁcant survival differences between the countries (Fig. 1B).
As shown in Figure 2B, representing stage III between 2007 and
2010, patients in Sweden and Norway received less adjuvant
chemotherapy compared with Belgium but had a signiﬁcantly
higher RS. For patients with stage IV colon cancer between
2007 and 2010 (Fig. 2C), low proportion of patients receiving
chemotherapy seemed to be associated with a signiﬁcantly
lower RS in Denmark, The Netherlands, and Norway.
DISCUSSION
This international population-based comparison shows sub-
stantial variation in treatment within ﬁve European countries
for patients with colon cancer aged 80 years or older, diagnosed
between 2001 and 2010. Variation was most pronounced in
adjuvant chemotherapy administration. Substantial variation in
survival was also observed. No clear pattern between the pro-
portion of chemotherapy and adjusted RS was found.
Patients and Tumor Characteristics
Stage distribution was comparable across participating coun-
tries, except for Denmark, where a lower proportion of stage I
and a higher proportion of stage IV was found. In countries
other than Denmark, there was a higher proportion of unknown
stage that might include a high proportion of patients with met-
astatic disease. Secondly, it is noteworthy that the number of
patients diagnosed with colon cancer aged 80 years and older
among participating countries in the current study is not always
in accordance with the ratio of the number of inhabitants in
each country. Possible explanations might be differences in pop-
ulation structure, differences in incidence rates in the older
community, or possible differences in early diagnostics.
Treatment Comparison
A notable ﬁnding in this study is that almost all patients with
stage II and III disease underwent surgical treatment. Only sur-
gical treatment for stage I was performed less often in Belgium
and Norway compared with other countries (DK, NL, and SE
>94%). On the contrary, for stage IV, surgical treatment was
performed more often in Belgium and Sweden (60%) com-
pared with other countries. The proportion of older patients
treated with adjuvant chemotherapy was highest in Belgium
and lowest in The Netherlands and Norway across all stages.
This substantial variation cannot be explained by differences
between the national guidelines of the participating countries
regarding adjuvant chemotherapy, as there were only minor
Table 2. Treatment strategies according to stage and period for patients aged 80 years and older diagnosed with colon
cancer (2001–2010)
2001–2006 Belgium Denmark Sweden The Netherlands Norway p value
Adjusted
p valuea
Surgery
Stage I 338 (86.4) 334 (97.4) — 860 (98.7) 678 (89.3) <.001 <.001
Stage II 1,152 (95.2) 1,164 (95.3) 2577 (96.5) 1215 (97.1) <.001 <.001
Stage III 825 (96.3) 744 (97.8) 1561 (98.8) 939 (98.3) <.001 .002
Stage IV 292 (61.1) 430 (47.8) 658 (54.7) 598 (64.4) <.001 <.001
Chemotherapy
Stage I 3 (0.9) 0 (0.0) — 1 (0.1) .004 .10
Stage II 56 (4.9) 8 (0.7) 3 (0.1) — <.001 <.001
Stage III 174 (21.1) 49 (6.6) 75 (4.8) <.001 <.001
Chemotherapy after surgery for metastatic disease
Stage IV 81 (27.7) 37 (8.6) 50 (7.6) <.001 <.001
2007–2010 Belgium Denmark Swedenb The Netherlands Norwayb p value
Adjusted
p valuea
Surgery
Stage I 598 (82.6) 223 (96.1) 470 (94.4) 849 (98.7) 499 (92.9) <.001 <.001
Stage II 1,899 (95.5) 856 (94.7) 1,477 (98.5) 2,021 (94.5) 1,126 (96.2) <.001 <.001
Stage III 1,401 (96.2) 551 (98.4) 1,020 (97.4) 1,381 (96.2) 773 (98.1) <.001 .001
Stage IV 521 (59.8) 298 (40.9) 503 (68.1) 525 (48.9) 301 (48.0) <.001 <.001
Chemotherapy
Stage I 5 (0.8) 3 (1.3) 0 (0.0) 0 (0.0) 2 (0.4) .02 .64
Stage II 92 (4.8) 14 (1.6) 8 (0.6) 3 (0.1) 9 (0.8) <.001 <.001
Stage III 347 (24.8) 91 (16.5) 72 (7.5) 85 (6.1) 30 (3.9) <.001 <.001
Chemotherapy after surgery for metastatic disease
Stage IV 203 (39.0) 65 (21.8) 70 (16.3) 78 (14.9) 31 (10.3) <.001 <.001
aAdjusted for sex, age, and incidence year.
bData on chemotherapy of low quality.
Abbreviation: —, no data.
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differences in these national guidelines. Only in The Nether-
lands, (neo)adjuvant chemotherapy was not indicated in the
case of resectable metastases (guidelines available on request).
The most common reasons for withholding adjuvant chemo-
therapy in older patients appear to be a combination of high
age, comorbidities, and poor performance status or refusal by
the patient or family [17].
Adjuvant chemotherapy after resection of the primary
tumor reduces the absolute risk of death by 3%–5% in stage II
with single-agent FU and 15%–20% in stage III with FU1
oxaliplatin combination [4]. However, frail elderly patients
are often excluded from trials. In the MOSAIC trial (FU/
leucovorin6 oxaliplatin in stage II and III colon cancer), eligible
patients were 18–75 years of age [18]. Subgroup analyses of
data from the MOSAIC trial, published in 2012, showed no sig-
niﬁcant beneﬁt (overall survival and disease-free survival) for
the addition of oxaliplatin to FU as adjuvant treatment for both
stage II and older patients (70–75 years) [19]. Single-agent FU is
therefore recommended as the treatment of choice for older
patients with high-risk stage II and stage III patients [4].
Figure 1. Proportion of patients receiving chemotherapy after surgery and adjusted RERs of death for patients 80 years and older diag-
nosed with stage II colon cancer (A), stage III colon cancer (B), and stage IV colon cancer (C), according to country (2001–2006).
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Survival
Between 2007 and 2010, for all stages combined, including
missing stage, 5-year RS was lowest in Belgium (52.2%) and
highest in Sweden (65.8%; supplemental online Table 1). As
shown by EUROCARE-5, the overall 5-year RS (all stages) for
patients with colon cancer in Europe was 57% but decreased to
49.3% in patients aged 75 years and older [12]. For patients
with colon cancer aged 80 years or older, there are no recent
published data on variation in survival between countries.
Direct comparison with EUROCARE is not possible because
these international comparisons included all ages and do not
provide further information on stage of disease and given
treatments.
Survival in Relation to Treatment
In all countries, almost all patients with stage II and III colon
cancer underwent surgical treatment. Unfortunately, no data
are available on the intent of surgery and surgical quality. No
clear linear pattern was observed between a higher proportion
of adjuvant chemotherapy and better adjusted RS. Remarkably,
Figure 2. Proportion of patients receiving adjuvant chemotherapy and adjusted RERs of death for patients 80 years and older diagnosed
with stage II colon cancer (A), stage III colon cancer (B), and stage IV colon cancer (C), according to country (2007–2010).
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for patients with stage II and III colon cancer in Sweden, signiﬁ-
cant differences in adjusted RERs are observed, indicating bet-
ter survival with less chemotherapy. Therefore, this survival
difference cannot be explained by beneﬁcial effects of adjuvant
chemotherapy, indicating a major role for quality of care. This
might be explained by the focus on improved colon cancer
treatment on a national level since 2004–2005 in Sweden,
including better preoperative work-up, improved surgery with
the concept of complete mesocolic excision, less acute resec-
tions, and better pathology assessment [20]. Several other
explanations for survival differences have previously been sug-
gested. These include demographic differences, differences in
lifestyle, stage at diagnosis, and health care systems, and differ-
ences in access to or use of effective treatment options [21].
However, one should consider the fact that data on chemother-
apy for some countries are of lower quality and compliance is
unknown. Differences in survival can also be caused by differ-
ences other than treatment, such as peri-operative care and
selection of patients. Only for patients with stage IV disease
between 2007 and 2010, Denmark, The Netherlands, and Nor-
way described less chemotherapy after surgical treatment and
showed lower adjusted RS compared with Belgium. However,
not the administration of chemotherapy but the higher propor-
tion of surgical treatment for stage IV colon cancer in Belgium
and Sweden may explain the higher survival rates in these two
countries.
Strengths and Limitations
This study is unique in comparing both treatment and RS
between European countries for patients aged 80 years or
older with colon cancer. This population-based study offers
insight in the use of surgery and adjuvant chemotherapy
among those elderly patients who are often excluded in clinical
trials. Observational data from cancer registries are highly rep-
resentative for the older population because there is no selec-
tion for inclusion. Furthermore, major strengths are the large
number of colon cancer cases included and representation of
different countries in Western and Northern Europe.
This study has some limitations. Most importantly, there
might be unknown differences in data registration between the
countries. Also, residual confounding by unmeasured factors
cannot be excluded, as no information was available on, among
others, vascular or lymphatic invasion, surgical quality, postop-
erative complications, chemotherapy compliance, and comor-
bidity. Finally, data for stage as well as emergency surgery were
incomplete and may have a substantial effect on outcomes.
Clinical Implications
With the increasing growth of the older population, clinicians
will be treating an increasing number of older patients diag-
nosed with colon cancer. Because no clear linear pattern
between adjuvant chemotherapy and better adjusted RS was
observed in the countries in this study, further detailed studies
are necessary to improve evidence for the indication of chemo-
therapy in the oldest population. Future studies should also
include data on surgical quality. However, quantifying surgical
quality remains challenging.
CONCLUSION
The present international comparison from the EURECCA colon
cancer group shows substantial variation in treatment for
patients diagnosed with colon cancer and aged 80 years or
older. Especially in higher stages of disease, variation in adju-
vant chemotherapy administration was pronounced. However,
no clear pattern between the proportion of chemotherapy and
better adjusted RS was observed.
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